Gene synthesis refers to the chemical synthesis of DNA strand base by base. Different DNA replication that occurs in cells or by Polymerase Chain Reaction (PCR), gene synthesis does not require a template strand. Rather, gene synthesis involves the step-wise addition of nucleotides to a single-stranded molecule, which then serves as a template for the creation of a complementary strand. Gene synthesis is the fundamental technology upon which the field of synthetic biology has been built.
Access Full Report @ https://www.databridgemarketresearch.com/jp/reports/india-gene-synthesis-market
The technological progressions in gene synthesis have modernized synthetic biology research. Scientists are no longer limited to classical methods of manipulating a single gene at a time; they now have the power to design or reprogram entire genomes and cells. The newly synthesized viral genomes are expected to boost vaccine development, eliminate cancer cells, and produce sustainable biofuels, in the coming future. We can detect and break down environmental pollutants in the soil, air, and water. Biotechnology and Life Science researchers and academia across many research discipline areas are accelerating the advancements in healthcare, agriculture, energy, and other fields of human endeavor, through the use of newly synthesized genomes.
Data Bridge Market Research analyses that the Gene Synthesis Market is expected to grow at a CAGR of 25.5% in the forecast period of 2023 to 2030 and is expected to reach USD 459.81 million by 2030. The component segment is projected to propel the growth of the market with the rising adoption of gene therapy, expansion of synthetic biology, and rising interest in gene synthesis in the field of molecular biology.
Key Findings of the Study
Increased Prevalence of Chronic Infectious Diseases
Bacterial and viral diseases are rapidly expanding due to the rising prevalence of infectious diseases in the world. As a result, the demand for novel and effective therapies has increased to fight against such deadly diseases. These diseases can be cured by using chemical drugs and biological therapies, including gene therapy.
By applying genomics, the management of infectious and endemic diseases has been enhanced. It also allows us to understand emerging drug resistance and identify targets for new therapeutics and vaccines. For the treatment of infectious diseases, gene therapy has attracted many researchers as it can be treated by using recombinant DNA technology, DNA &RNA ribozyme, and single-chain antibodies. With a rising need for personalized treatments, drug development, vaccine research, and diagnostics tailored to the specific genetic characteristics of pathogens and individuals, gene synthesis becomes a pivotal tool. Investments in R&D and infrastructure are expected to increase as the Indian healthcare system and biotechnology sector pivot to tackle these diseases. This, in turn, is expected to drive market growth, offering novel avenues for the creation of targeted therapies, rapid vaccine development, precise diagnostics, and in-depth genetic research focused on chronic infectious diseases.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 – 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Component (Synthesizer, Consumables, and Software & Services), Gene Type (Standard Gene, Express Gene, Complex Gene, and Others), Gene Synthesis Type (Gene Library Synthesis and Custom Gene Synthesis), Application (Synthetic Biology, Genetic Engineering, Vaccine Design, Therapeutic Antibodies, and Others), Method (PCR-Based Enzyme Synthesis, Chip-Based DNA Synthesis, and Solid Based Synthesis), End User, (Academic & Research Institutes, Diagnostic Laboratories, Biotech & Pharmaceutical Companies, Contract Research Organizations (CROs), Agriculture, Food, and Others), Distribution Channel (Direct Tender, Online Distributions, and Third Party Distributors)
|
|
Country Covered
|
India
|
|
Market Players Covered
|
Thermo Fisher Scientific Inc. (U.S.), Boster Biological Technology (U.S.), Twist Bioscience (U.S.), OriGene Technologies, Inc. (U.S.), Eurofins Scientific (Luxembourg), GenScript (U.S.), Merck KGaA (Germany), Kaneka Eurogentec S.A (Belgium), Synbio Technologies (China), GCC Biotech (INDIA) Pvt. Ltd. (India) among others.
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The India gene synthesis market is segmented on the basis of component, gene type, gene synthesis type, application, method, end user, and distribution channel.
- On the basis of component, the market is segmented into synthesizer, consumables, and software & services.
In 2023, the software and services segment of the component segment is expected to dominate the market
In 2023, the software & services segment is expected to dominate the market with 49.99% market share due to product approval received improved workflow of sequencing and software and services which offer significant reductions in DNA synthesis cost due to their dense and massively parallel feature designs.
- On the basis of gene type, the market is segmented into standard gene, express gene, complex gene, and others.
In 2023, the standard gene segment of the gene type segment is expected to dominate the market
In 2023, the standard gene segment is expected to dominate the market with 48.39% market share due to the standard genes with high phenotypes having great variation in expression.
- On the basis of gene synthesis type, the market is segmented into gene library synthesis and custom gene synthesis. In 2023, the custom gene synthesis segment is expected to dominate the market with a market share of 65.40%.
- On the basis of application, the market is segmented into synthetic biology, genetic engineering, vaccine design, therapeutic antibodies, and others. In 2023, the synthetic biology segment is expected to dominate the market with a market share of 41.94%.
- On the basis of method, the India gene synthesis market is segmented into solid phase synthesis, chip-based DNA synthesis, and PCR-based enzyme synthesis. In 2023, the PCR-based enzyme synthesis segment is expected to dominate the market with a market share of 53.81%.
- On the basis of end user, the market is segmented into academic & research institutes, diagnostic laboratories, biotech & pharmaceutical companies, contract research organizations (CROs), agriculture, food, and others. In 2023, the academic & research institutes segment is expected to dominate the market with a market share of 54.02%.
- On the basis of distribution channel, the market is segmented into direct tender, online distribution, and third party distributors. In 2023, the direct tender segment is expected to dominate the market with a market share of 51.19%.
Major Players
Data Bridge Market Research recognizes the following companies as the major market players in the market are Thermo Fisher Scientific Inc. (U.S.) Merck KGaA (Germany), Kaneka Eurogentec S.A (Belgium), Synbio Technologies (China), and GCC Biotech (INDIA) Pvt. Ltd. (India), Eurofins Scientific (Luxembourg), GenScript (U.S.), among others.
Market Development
- In August 2022, Thermo Fisher Scientific Inc. announced that they had launched Applied Biosystems HIV-1 Genotyping Kit with Integrase, which will help to examine positive samples of the human immunodeficiency virus (HIV) to identify genetic variants that resist common antiretroviral therapeutics.
- In March 2022, Thermo Fisher Scientific Inc. collaborated with Structura Biotechnology Inc., a leading provider of cryo-EM data analysis software, to make available a new single particle analysis software solution, a version of structures CryoSPARC Live that is designed to integrate with Thermo Fisher’s Smart EPU software and cryo-transmission electron microscope (cryo-TEM) technology.
- In February 2022, Kaneka Eurogentec announced that its mRNA manufacturing facility has successfully produced a 25 g batch of mRNA for a US customer. This quantity is equivalent to 100,000’s to millions of doses of mRNA, potentially sufficient for late clinical and commercial uses.
- In September 2021, Eurofins Scientific Collaborate with Transplant Genomics to launch omnigra, the only combination biomarker panel that provides the earliest indication of rejection in kidney transplant recipients as it provides significantly higher positive predictive value (PPV) and negative predictive value (NPV) than any other kidney rejection assays (or tests) on the market.
For more detailed information about the India gene synthesis market report, click here – https://www.databridgemarketresearch.com/jp/reports/india-gene-synthesis-market
